A Phase 2 Single-Arm Open-Label Extension Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study 1311.5
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Risankizumab (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions
- Sponsors AbbVie
- 07 Jul 2017 Planned End Date changed from 25 Aug 2018 to 15 Oct 2018.
- 07 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Dec 2016 New trial record